Data security is the practice of protecting digital information from unauthorized access, corruption, or theft throughout its entire lifecycle. For biotech companies working in genetics, this challenge is especially acute. Sensitive data, including genomic sequences, patient health information, and clinical trial records, moves across platforms, devices, cloud environments, and third-party vendor systems. Protecting that data at every stage is not optional. It is foundational to responsible research and long-term operational viability.
The volume and sensitivity of data held by biotech companies makes privacy-first, security-led software engineering essential for both sponsors and their vendor partners. Understanding the distinction between data security and data privacy is a necessary starting point.
Data security focuses on how information is protected, through encryption, access controls, authentication protocols, and infrastructure design. Data privacy addresses how data is collected, stored, processed, and shared, and whether those practices comply with applicable regulations. Both must be addressed together, but they require different controls and governance frameworks.
When data privacy or security are compromised, the consequences are significant:
For companies operating in precision medicine, the regulatory landscape adds another layer of complexity. Frameworks such as the Health Insurance Portability and Accountability Act (HIPAA), the European Union's General Data Protection Regulation (GDPR), and the California Consumer Privacy Act (CCPA) each define specific obligations around how personal and health data must be handled. Genetic data, in particular, often falls under the most sensitive classification within these frameworks, requiring heightened protections for collection, storage, processing, and cross-border transfer.
Meeting these requirements is not solely an internal challenge. Every vendor, lab partner, and technology platform in the data chain must also operate within the same compliance boundaries. This means that vendor selection is itself a data security decision, one that directly affects a company's risk posture and regulatory standing.
Effective data security in biotech requires multiple layers of protection working together. These typically include:
For companies managing genetic data within clinical research workflows, these measures must extend across every system and partner involved in participant recruitment, testing, consent, and engagement.
Companies that treat security as an ongoing operational commitment, rather than a compliance checkbox, are better positioned to protect their participants, their data assets, and their ability to execute research programs at scale.
Download the report for a structured overview of the security and privacy practices biotech companies should evaluate when selecting vendor partners.
Sano Genetics is ISO 27001 certified and compliant with both HIPAA and GDPR. Our security practices include regular audits, penetration testing, and the option for deployment on dedicated infrastructure. To learn more about how we approach data security across the precision medicine lifecycle, get in touch.
Data security in biotech is not a one-time implementation. It is a continuous discipline that spans the full data lifecycle, from the moment a participant consents to testing through long-term data storage and potential recontact.
Q: What is data security?
Data security is the practice of protecting digital information from unauthorized access, corruption, or theft across its entire lifecycle. It covers hardware, software, storage systems, user devices, access controls, and the policies that govern how data is handled. For biotech companies managing genomic and clinical data, this means maintaining confidentiality, integrity, and availability of that information at every stage, from collection through long-term storage.
Q: What is the difference between data security and data privacy?
Data security refers to the technical and organizational controls that prevent unauthorized access or misuse of data. Data privacy governs how data is collected, used, shared, and retained. Security is the mechanism; privacy is the standard it supports.
Regulations such as GDPR and HIPAA define what privacy requires. Data security measures, including encryption, access controls, and audit logging, are how organizations demonstrate they meet those requirements in practice.
Q: What types of data security measures should biotech companies use?
Biotech companies handling genomic or clinical data need multiple layers of protection. Key measures include:- Encryption: Protecting data in transit and at rest so it cannot be read if intercepted.- Access controls: Ensuring only authorized personnel can view or modify sensitive data.- Data masking: Replacing identifiable information with anonymized values in non-production environments.- Audit logging: Recording who accesses data and when, to support both oversight and incident response.- Vulnerability management: Identifying and remediating security weaknesses before they can be exploited.
Vendors working with biotechs should be able to demonstrate each of these controls and align them to recognized frameworks such as ISO 27001 or SOC 2.
Q: What are the risks of poor data security in biotech?
Poor data security in biotech creates risks across multiple dimensions. A breach can expose participant genomic or health data, which is among the most sensitive categories of personal information. Regulatory penalties under GDPR, HIPAA, or other applicable frameworks can follow.
Beyond fines, the reputational damage can undermine participant trust and affect an organization's ability to recruit for future studies. Intellectual property, including proprietary research or discovery data, may also be compromised. For companies working in genetics, the nature of the data amplifies each of these consequences.
Q: How should biotech companies evaluate vendor data security practices?
Biotech companies should assess vendors against recognized security standards before sharing any sensitive data. Key areas to evaluate include:- Whether the vendor holds certifications such as ISO 27001 or has completed a SOC 2 audit.- How data is encrypted in transit and at rest.- What access control policies are in place and how they are enforced.- How the vendor manages subprocessors who may also handle the data.- What incident response procedures exist and how quickly breaches are reported.
A vendor's security posture directly affects the biotech's own compliance obligations. Weak vendor controls become the biotech's liability.